Opinion|Videos|September 19, 2024
Clinical Scenario: Treatment Selection in the third line and beyond in cGVHD
Medical experts discuss treatment selection for a specific clinical scenario.
Advertisement
Video content above is prompted by the following:
Dr Holtan: Please read this clinical scenario: Four months after having undergone allogenic hematopoietic stem transplant, a patient presents to the clinic with rashes over a large portion of his body and dry eyes. Based on clinical presentation and lab results, a diagnosis of moderate cGVHD is established. Patient was treated with steroids and subsequent calcineurin inhibitors for 4 to 6 weeks but showed little improvement in cGVHD symptoms.
- Dr Ali:What other treatments could be used in such patients once steroid refractoriness is established?
- Are there factors you consider when choosing an alternate treatment option (efficacy, safety profile, clinical manifestations)?
Advertisement
Related to this article
A pilot study represents a milestone toward testing a faster, more powerful, and potentially less-toxic form of radiation therapy for cancer treatment.
Oral azacitidine and cedazuridine met the end point of total cycle azacitidine exposure vs subcutaneous azacitidine in MDS or CMML.
UTRxMYCN M1-14 received orphan drug status for soft tissue sarcoma and RPDD for rhabdomyosarcoma.
Interim data showed that the BCMA-directed CAR T-cell therapy NXC-201 generated complete responses in relapsed/refractory AL amyloidosis.
Estelamari Rodriguez, MD, MPH, discusses the rationale, design, and practice implications of the phase 3 RELATIVITY-1093 trial in nonsquamous NSCLC.
Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.
The third BLA submission for tabelecleucel follows 2 CRLs and includes updated ALLELE data with additional patients and longer follow-up.
A New England Journal of Medicine report describes complete hepatoblastoma regression in a 3-year-old treated with a novel immunotherapy.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Plinabulin Plus Docetaxel in Post-ICI Non-Squamous NSCLC
2
Breast Cancer Experts Highlight Abstracts to Watch at ESMO 2026
3
Navigating DLL3-Targeting T-Cell Engagers and the Evolving Small Cell Lung Cancer Treatment Landscape
4
FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy
5